BioCentury | Apr 27, 2018
Company News

UCB buys rights to seizure candidate

...rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen...
BioCentury | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

...rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen...
...of sodium channels and modulates collapsin response mediator protein-2 (DPYSL2; CRMP-2). Elizabeth S. Eaton USL261, iti-111, Intranasal midazolam Proximagen UCB...
BioCentury | Feb 8, 2016
Company News

Saniona, Upsher-Smith deal

...Upsher-Smith’s Proximagen Ltd. subsidiary and Saniona partnered to discover small molecule therapies for CNS indications using...
...Saniona partnered to discover small molecule therapies for CNS indications using Saniona’s ion channel technology. Proximagen...
BioCentury | Jan 4, 2016
Company News

Upsher-Smith, Roche deal

...Upsher-Smith’s Proximagen Ltd. subsidiary granted Roche exclusive, worldwide rights to develop and commercialize an oral small...
...effective in treatment of inflammatory diseases. The compound is in Phase II testing. Roche and Proximagen...
...additional Phase II trials, and Roche will assume responsibility for late-stage development and worldwide commercialization. Proximagen...
BioCentury | Dec 8, 2014
Company News

Upsher-Smith, MRC deal

...Upsher-Smith’s Proximagen Ltd. U.K. subsidiary and MRC partnered to identify and develop small molecules targeting macrophage...
...develop small molecules targeting macrophage migration inhibitory factor (MIF) to treat inflammatory and autoimmune disease. Proximagen...
...develop MIF inhibitors through proof of concept in animal models and then identify commercial partners. Proximagen...
BioCentury | Nov 13, 2014
Translation in Brief

Translational tidbits

...to identify inhibitors of TNKS and TNKS2 to treat various cancers (Continues on p. 7) Proximagen Group plc...
BioCentury | Oct 7, 2013
Company News

Upsher-Smith, Lundbeck deal

...H. Lundbeck for the preclinical development of Proximagen's protein kinase inhibitors. In 2012, Upsher-Smith acquired Proximagen...
BioCentury | Dec 17, 2012
Company News

Q Chip management update

...delivery Hired: Tim Sparey as CEO and a director, formerly head of business development at Proximagen Group plc...
BioCentury | Aug 20, 2012
Company News

Proximagen, Upsher-Smith deal

...Upsher-Smith completed its acquisition of the 84% of Proximagen it did not already own for 320p...
...320p per share in cash, or about £223 million ($349.3 million) (see BioCentury, June 18). Proximagen Group plc...
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

...research tool supplier completed its acquisition of rabbit mAbs supplier Epitomics Inc. in April.In addition, Proximagen Group plc...
...million ($409.1 million). In June, Upsher-Smith Laboratories Inc. said it will acquire the 84% of Proximagen...
Items per page:
1 - 10 of 52
BioCentury | Apr 27, 2018
Company News

UCB buys rights to seizure candidate

...rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen...
BioCentury | Apr 20, 2018
Company News

UCB buys rights to seizure candidate

...rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen...
...of sodium channels and modulates collapsin response mediator protein-2 (DPYSL2; CRMP-2). Elizabeth S. Eaton USL261, iti-111, Intranasal midazolam Proximagen UCB...
BioCentury | Feb 8, 2016
Company News

Saniona, Upsher-Smith deal

...Upsher-Smith’s Proximagen Ltd. subsidiary and Saniona partnered to discover small molecule therapies for CNS indications using...
...Saniona partnered to discover small molecule therapies for CNS indications using Saniona’s ion channel technology. Proximagen...
BioCentury | Jan 4, 2016
Company News

Upsher-Smith, Roche deal

...Upsher-Smith’s Proximagen Ltd. subsidiary granted Roche exclusive, worldwide rights to develop and commercialize an oral small...
...effective in treatment of inflammatory diseases. The compound is in Phase II testing. Roche and Proximagen...
...additional Phase II trials, and Roche will assume responsibility for late-stage development and worldwide commercialization. Proximagen...
BioCentury | Dec 8, 2014
Company News

Upsher-Smith, MRC deal

...Upsher-Smith’s Proximagen Ltd. U.K. subsidiary and MRC partnered to identify and develop small molecules targeting macrophage...
...develop small molecules targeting macrophage migration inhibitory factor (MIF) to treat inflammatory and autoimmune disease. Proximagen...
...develop MIF inhibitors through proof of concept in animal models and then identify commercial partners. Proximagen...
BioCentury | Nov 13, 2014
Translation in Brief

Translational tidbits

...to identify inhibitors of TNKS and TNKS2 to treat various cancers (Continues on p. 7) Proximagen Group plc...
BioCentury | Oct 7, 2013
Company News

Upsher-Smith, Lundbeck deal

...H. Lundbeck for the preclinical development of Proximagen's protein kinase inhibitors. In 2012, Upsher-Smith acquired Proximagen...
BioCentury | Dec 17, 2012
Company News

Q Chip management update

...delivery Hired: Tim Sparey as CEO and a director, formerly head of business development at Proximagen Group plc...
BioCentury | Aug 20, 2012
Company News

Proximagen, Upsher-Smith deal

...Upsher-Smith completed its acquisition of the 84% of Proximagen it did not already own for 320p...
...320p per share in cash, or about £223 million ($349.3 million) (see BioCentury, June 18). Proximagen Group plc...
BioCentury | Jul 2, 2012
Finance

2Q Stock Wrap-Up: Magic in mid-caps

...research tool supplier completed its acquisition of rabbit mAbs supplier Epitomics Inc. in April.In addition, Proximagen Group plc...
...million ($409.1 million). In June, Upsher-Smith Laboratories Inc. said it will acquire the 84% of Proximagen...
Items per page:
1 - 10 of 52